Stock TCRX TSCAN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company TScan Therapeutics, Inc.

Equities

TCRX

US89854M1018

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
7.29 USD -1.22% Intraday chart for TScan Therapeutics, Inc. +5.35% +25.04%
Apr. 19 TScan Therapeutics Closes $150.1 Million Securities Offering MT
Apr. 17 TScan Therapeutics Prices $150.1 Million Public Offering of Shares, Warrants MT

Business Summary

TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in clinical development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, a collection of solid tumor targets across different Human leukocyte antigens (HLAs) types in the TCR field. The Company is advancing approximately six solid tumor programs: TSC-204, TSC-200, TSC-203, TSC-201, TSC-202 and TSC-205.

Number of employees: 154

Sales per Business

USD in Million2022Weight2023Weight Delta
T Cell Receptor-engineered T Cell
100.0 %
14 100.0 % 21 100.0 % +55.52%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
14 100.0 % 21 100.0 % +55.52%

Managers

Managers TitleAgeSince
Gavin MacBeath CEO
 Chief Executive Officer 54 18-11-30
Jason Amello DFI
 Director of Finance/CFO 55 Jan. 28
Justin McCue CTO
 Chief Tech/Sci/R&D Officer - Dec. 03
Ray Lockard CTO
 Chief Tech/Sci/R&D Officer - 23-04-05
Shrikanta Chattopadhya CTO
 Chief Tech/Sci/R&D Officer - -
Heather Savelle IRC
 Investor Relations Contact - 21-10-04
Leiden Dworak AUD
 Comptroller/Controller/Auditor - 22-04-10
Zoran Zdraveski LAW
 General Counsel 54 21-09-08
Ann Hargraves HRO
 Human Resources Officer - 20-08-31

Members of the board

Members of the board TitleAgeSince
Timothy Barberich CHM
 Chairman 76 19-02-28
Stephen Biggar BRD
 Director/Board Member 53 21-02-28
Gavin MacBeath CEO
 Chief Executive Officer 54 18-11-30
Barbara Klencke BRD
 Director/Board Member 66 23-04-05
Katina Dorton BRD
 Director/Board Member 66 21-03-22
R. Woods BRD
 Director/Board Member 57 Dec. 05
Gabriela Gruia BRD
 Director/Board Member 67 21-05-26

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 4,276,588 0 0 90.66 %
Stock B 1 46,025,522 45,605,607 ( 99.09 %) 0

Shareholders

NameEquities%Valuation
Lynx1 Capital Management LP
11.98 %
5,224,600 11.98 % 41 M $
EcoR1 Capital, LLC
11.47 %
5,000,000 11.47 % 40 M $
Adage Capital Partners GP LLC
8.944 %
3,900,000 8.944 % 31 M $
BVF, Inc.
6.856 %
2,989,474 6.856 % 24 M $
Baker Bros. Advisors LP
6.386 %
2,784,792 6.386 % 22 M $
Baker Bros. Advisors LP
6.386 %
2,784,792 6.386 % 22 M $
Christoph H. Westphal
5.310 %
2,315,423 5.310 % 18 M $
Propel Bio Management LLC
4.786 %
2,087,139 4.786 % 17 M $
Pitango Venture Capital
4.770 %
2,079,985 4.770 % 17 M $
Vanguard Global Advisers LLC
4.101 %
1,788,152 4.101 % 14 M $
NameEquities%Valuation
Baker Bros. Advisors LP
42.77 %
4,276,588 42.77 % 34 M $

Company contact information

TScan Therapeutics, Inc.

830 Winter Street

02451, Waltham

+

http://www.tscan.com
address TScan Therapeutics, Inc.(TCRX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Ratings for TScan Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
7.29 USD
Average target price
11.6 USD
Spread / Average Target
+59.12%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
TSCAN THERAPEUTICS, INC. Stock TScan Therapeutics, Inc.
+25.04% 349M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.12% 42.59B
MODERNA, INC. Stock Moderna, Inc.
+6.77% 40.65B
LONZA GROUP AG Stock Lonza Group AG
+45.26% 40.57B
CELLTRION, INC. Stock Celltrion, Inc.
-11.96% 26.77B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.01% 24.81B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.92% 18.17B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.63% 11.7B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.16% 12.05B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.30% 11.1B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. TCRX Stock
  4. Company TScan Therapeutics, Inc.